Comparison
Pasireotid vs. Selank
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
396091-73-9
129954-34-3
Molecular weight
1047.21 g/mol
751.85 g/mol
Half-life
no data
0.3 h
Sequence
no data
Thr-Lys-Pro-Arg-Pro-Gly-ProMechanism of action
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
1
4
of which in humans
1
2
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Pasireotid and Selank?
- Pasireotid is classified as "Research other", while Selank is classified as "Research other". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Pasireotid or Selank?
- The highest available evidence level is "Human RCT" for Pasireotid and "Human trial" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Pasireotid and Selank in Germany and the United States?
- Germany: Pasireotid — Prescription, Selank — Unapproved. United States: Pasireotid — Prescription, Selank — Unapproved. These are factual summaries with source and review date on the individual pages.